All In Biotech

Drug Trial Radar · NCT01039376

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Maintenance Treatment Versus no Further Treatment in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) Who Have Responded to Induction Therapy

Last checked: Nov 20, 2026Latest source record: Jul 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

480

Actual

Start

May 6, 2010

Primary completion

Feb 20, 2017

Study completion Jun 26, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 25, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine if maintenance therapy with ofatumumab would prolong remission in patients with CLL who have responded to second or third line treatment. This study would also evaluate the safety of ofatumumab maintenance compared to observation (the current standard of care). This study was co-developed with the HOVON and NORDIC CLL group and would be conducted as a collaborative effort with GSK.

Conditions

  • Leukaemia, Lymphocytic, Chronic

Interventions

  • OfatumumabBiological

    Ofatumumab for maintenance therapy as IV infusions every 8 weeks . The first dose was 300 mg followed 1 week later by 1000 mg and 1000 mg every 8 weeks thereafter for up to 2 years.

  • ObservationOther

    Observation/Safety Evaluation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival, as Assessed by the InvestigatorTime frame: From randomization until progression or death (up to 79 months)
  2. Progression-free Survival, as Assessed by the Independent Review Committee (IRC)Time frame: From randomization until progression or death (up to 79 months)

Locations

203 sites in 25 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Gilbert, Arizona

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Jonesboro, Arkansas

  • Novartis Investigative Site

    Berkeley, California

  • Novartis Investigative Site

    La Verne, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    San Pablo, California

  • Novartis Investigative Site

    Hartford, Connecticut

  • Novartis Investigative Site

    Gainesville, Florida

  • Novartis Investigative Site

    Lake Worth, Florida

  • Novartis Investigative Site

    Orlando, Florida

  • Novartis Investigative Site

    Pembroke Pines, Florida

  • Novartis Investigative Site

    West Palm Beach, Florida

  • Novartis Investigative Site

    Macon, Georgia

  • Novartis Investigative Site

    Savannah, Georgia

  • Novartis Investigative Site

    Post Falls, Idaho

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    Iowa City, Iowa

  • Novartis Investigative Site

    Westwood, Kansas

  • Novartis Investigative Site

    Metairie, Louisiana

  • Novartis Investigative Site

    Cumberland, Maryland

  • Novartis Investigative Site

    Hagerstown, Maryland

  • Novartis Investigative Site

    Worcester, Massachusetts

  • Novartis Investigative Site

    Detroit, Michigan

  • Novartis Investigative Site

    Springfield, Missouri

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    Henderson, Nevada

  • Novartis Investigative Site

    New Brunswick, New Jersey

  • Novartis Investigative Site

    Albuquerque, New Mexico

  • Novartis Investigative Site

    Albuquerque, New Mexico

  • Novartis Investigative Site

    Mineola, New York

  • Novartis Investigative Site

    Rochester, New York

  • Novartis Investigative Site

    Chapel Hill, North Carolina

  • Novartis Investigative Site

    Durham, North Carolina

  • Novartis Investigative Site

    Philadelphia, Pennsylvania

  • Novartis Investigative Site

    Greenville, South Carolina

  • Novartis Investigative Site

    Chattanooga, Tennessee

  • Novartis Investigative Site

    Knoxville, Tennessee

Showing 40 of 203 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.